Abstract
Allergic rhinitis (AR) is caused by an immediate type hypersensitivity reaction in sensitized subjects after exposure to airborn allergens. The interaction of the allergen with a specific IgE antibody attached to the nasal mast cells leads to the local release of vasoactive and inflammatory mediators such as histamine, leukotriene C4 and prostaglandin D2. These mediators cause the nasal allergic symptoms complex of rhinorrhea, nasal obstruction, nasal itching and sneezing, which improve spontaneously or with treatment. Cromolyn sodium and nedocromil sodium are often termed ‘antiallergic drugs’, which are defined here as drugs capable of inhibiting both the early-phase response to challenge and chronic allergic inflammation. They act at the cell membrane levels. Intranasal and ocular formulations of cromones, such as cromoglycate, are available without medical prescription in many countries. Sodium cromoglycate or nedocromil have a good safety profile. They reduce the symptoms of AR, and should be used profilactically, but limited efficacy and the need for frequent dosing are disadvantages.
Keywords: Allergic rhinitis, cromones, cromolyn sodium, nedocromil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Mast Cell Stabilizers in the Treatment of Allergic Rhinitis
Volume: 7 Issue: 1
Author(s): Ilknur Haberal Can and Ethem Erdal Samim
Affiliation:
Keywords: Allergic rhinitis, cromones, cromolyn sodium, nedocromil
Abstract: Allergic rhinitis (AR) is caused by an immediate type hypersensitivity reaction in sensitized subjects after exposure to airborn allergens. The interaction of the allergen with a specific IgE antibody attached to the nasal mast cells leads to the local release of vasoactive and inflammatory mediators such as histamine, leukotriene C4 and prostaglandin D2. These mediators cause the nasal allergic symptoms complex of rhinorrhea, nasal obstruction, nasal itching and sneezing, which improve spontaneously or with treatment. Cromolyn sodium and nedocromil sodium are often termed ‘antiallergic drugs’, which are defined here as drugs capable of inhibiting both the early-phase response to challenge and chronic allergic inflammation. They act at the cell membrane levels. Intranasal and ocular formulations of cromones, such as cromoglycate, are available without medical prescription in many countries. Sodium cromoglycate or nedocromil have a good safety profile. They reduce the symptoms of AR, and should be used profilactically, but limited efficacy and the need for frequent dosing are disadvantages.
Export Options
About this article
Cite this article as:
Can Haberal Ilknur and Samim Erdal Ethem, Mast Cell Stabilizers in the Treatment of Allergic Rhinitis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769177
DOI https://dx.doi.org/10.2174/187152308783769177 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Overlaps in the Nosology of Substance Abuse and Overeating: The Translational Implications of “Food Addiction”
Current Drug Abuse Reviews Modified-Release Solid Formulations for Colonic Delivery
Recent Patents on Drug Delivery & Formulation Influence of Chronic Kidney Disease Development and Renin-angiotensin System Inhibition on Cardiovascular Prognosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors
Current Pediatric Reviews Management of Idiopathic Intracranial Hypertension During the COVID-19 Pandemic
Reviews on Recent Clinical Trials Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Current Pharmaceutical Design Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Liver Fibrosis and Therapeutic Strategies: The Goal for Improving Metabolism
Current Drug Targets Renal Complications of Fabry Disease
Current Pharmaceutical Design L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology Elevated Plasma Level of D-dimer Predicts the High Risk of Early Cognitive Impairment in Type 2 Diabetic Patients as Carotid Artery Plaques become Vulnerable or Get Aggravated
Current Alzheimer Research Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design The Possible Involvement of HLA Class III Haplotype (RAGE, HSP70 and TNF Genes) in Alzheimer's Disease
Current Alzheimer Research